Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Hyman

Showing results (71-80 of 174) with videos related to

Pageof 18
Sort By:
Cancer Research|September 28, 2017
Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its InhibitionRona Yaeger, Zhan Yao, David M Hyman, et al.
The Journal of Molecular Diagnostics : JMD|December 22, 2018
Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer: Potential Implications for Clinical ManagementSounak Gupta, Chad M Vanderbilt, Paolo Cotzia, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 15, 2018
A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian CancerKatherine LaVigne, David M Hyman, Qin C Zhou, et al.
Cell Stem Cell|August 15, 2017
Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical OutcomesCatherine C Coombs, Ahmet Zehir, Sean M Devlin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2019
TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver MutationsEzra Y Rosen, Debra A Goldman, Jaclyn F Hechtman, et al.
JCO Precision Oncology|September 11, 2020
Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring <i>BRAF</i> <sup>V600</sup> Mutations: A Cohort of the Histology-Independent VE-BASKET StudyNoopur Raje, Ian Chau, David M Hyman, et al.
Cancer Discovery|February 8, 2020
Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i> <sup>V600</sup>-Mutant Non-Melanoma CancersVivek Subbiah, Igor Puzanov, Jean-Yves Blay, et al.
Cancers|November 7, 2020
Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative AnalysisAntoine Italiano, Shivani Nanda, Andrew Briggs, et al.
The Lancet. Oncology|March 30, 2019
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trialVicky Makker, Drew Rasco, Nicholas J Vogelzang, et al.
Current Problems in Cancer|April 18, 2021
Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving LarotrectinibShivaani Kummar, Jordan Berlin, Leo Mascarenhas, et al.
Pageof 18

Showing results (71-80 of 174) with videos related to

Sort By:
Pageof 18
Cancer Research|September 28, 2017
Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its InhibitionRona Yaeger, Zhan Yao, David M Hyman, et al.
The Journal of Molecular Diagnostics : JMD|December 22, 2018
Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer: Potential Implications for Clinical ManagementSounak Gupta, Chad M Vanderbilt, Paolo Cotzia, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 15, 2018
A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian CancerKatherine LaVigne, David M Hyman, Qin C Zhou, et al.
Cell Stem Cell|August 15, 2017
Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical OutcomesCatherine C Coombs, Ahmet Zehir, Sean M Devlin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2019
TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver MutationsEzra Y Rosen, Debra A Goldman, Jaclyn F Hechtman, et al.
JCO Precision Oncology|September 11, 2020
Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring <i>BRAF</i> <sup>V600</sup> Mutations: A Cohort of the Histology-Independent VE-BASKET StudyNoopur Raje, Ian Chau, David M Hyman, et al.
Cancer Discovery|February 8, 2020
Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i> <sup>V600</sup>-Mutant Non-Melanoma CancersVivek Subbiah, Igor Puzanov, Jean-Yves Blay, et al.
Cancers|November 7, 2020
Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative AnalysisAntoine Italiano, Shivani Nanda, Andrew Briggs, et al.
The Lancet. Oncology|March 30, 2019
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trialVicky Makker, Drew Rasco, Nicholas J Vogelzang, et al.
Current Problems in Cancer|April 18, 2021
Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving LarotrectinibShivaani Kummar, Jordan Berlin, Leo Mascarenhas, et al.
Pageof 18